Skip to main navigation Skip to search Skip to main content

Challenges, limitations, and pitfalls of PET and advanced MRI in patients with brain tumors: A report of the PET/RANO group

  • Norbert Galldiks*
  • , Timothy J. Kaufmann
  • , Philipp Vollmuth
  • , Philipp Lohmann
  • , Marion Smits
  • , Michael C. Veronesi
  • , Karl-Josef Langen
  • , Roberta Rudà
  • , Nathalie L. Albert
  • , Elke Hattingen
  • , Ian Law
  • , Markus Hutterer
  • , Riccardo Soffietti
  • , Michael A. Vogelbaum
  • , Patrick Y. Wen
  • , Michael Weller
  • , Joerg-Christian Tonn
  • *Corresponding author for this work
  • University of Cologne
  • Jülich Research Centre
  • Centrum für Integrierte Onkologie
  • Mayo Clinic Rochester, MN
  • Heidelberg University 
  • RWTH Aachen University
  • Erasmus University Rotterdam
  • University of Wisconsin-Madison
  • University of Turin
  • Ludwig Maximilian University of Munich
  • German Cancer Research Center
  • Goethe University Frankfurt
  • University of Copenhagen
  • Hospital of St. John of God
  • Moffitt Cancer Center
  • Dana-Farber Cancer Institute
  • University of Zurich

Research output: Contribution to journalReview articleAcademicpeer-review

49 Downloads (Pure)

Abstract

Brain tumor diagnostics have significantly evolved with the use of positron emission tomography (PET) and advanced magnetic resonance imaging (MRI) techniques. In addition to anatomical MRI, these modalities may provide valuable information for several clinical applications such as differential diagnosis, delineation of tumor extent, prognostication, differentiation between tumor relapse and treatment-related changes, and the evaluation of response to anticancer therapy. In particular, joint recommendations of the Response Assessment in Neuro-Oncology (RANO) Group, the European Association of Neuro-oncology, and major European and American Nuclear Medicine societies highlighted that the additional clinical value of radiolabeled amino acids compared to anatomical MRI alone is outstanding and that its widespread clinical use should be supported. For advanced MRI and its steadily increasing use in clinical practice, the Standardization Subcommittee of the Jumpstarting Brain Tumor Drug Development Coalition provided more recently an updated acquisition protocol for the widely used dynamic susceptibility contrast perfusion MRI. Besides amino acid PET and perfusion MRI, other PET tracers and advanced MRI techniques (e.g. MR spectroscopy) are of considerable clinical interest and are increasingly integrated into everyday clinical practice. Nevertheless, these modalities have shortcomings which should be considered in clinical routine. This comprehensive review provides an overview of potential challenges, limitations, and pitfalls associated with PET imaging and advanced MRI techniques in patients with gliomas or brain metastases. Despite these issues, PET imaging and advanced MRI techniques continue to play an indispensable role in brain tumor management. Acknowledging and mitigating these challenges through interdisciplinary collaboration, standardized protocols, and continuous innovation will further enhance the utility of these modalities in guiding optimal patient care.
Original languageEnglish
Pages (from-to)1181-1194
JournalNeuro-oncology
Volume26
Issue number7
DOIs
Publication statusPublished - 1 Jul 2024
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Challenges, limitations, and pitfalls of PET and advanced MRI in patients with brain tumors: A report of the PET/RANO group'. Together they form a unique fingerprint.

Cite this